(Q33414445)

English

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sung-Hyun Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hari Menon

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Saengsuree Jootar

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tapan Saikia

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jae-Yong Kwak

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang-Kyun Sohn

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joon Seong Park

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Seong Hyun Jeong

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hyeoung Joon Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yeo-Kyeoung Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suk Joong Oh

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hawk Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dae Young Zang

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joo Seop Chung

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ho Jin Shin

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Young Rok Do

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeong-A Kim

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dae-Young Kim

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chul Won Choi

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sahee Park

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hye Lin Park

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gong Yeal Lee

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dae Jin Cho

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jae Soo Shin

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dong-Wook Kim

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

4 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1191-1196

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Evolution of therapies for chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Chronic myeloid leukemia in Asia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Defining and managing imatinib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Loss of response to imatinib: mechanisms and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

The molecular biology of chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

The biology of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

14 July 2018

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

CML treatment in Asia-Pacific region

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077080

31 October 2018

Identifiers

10.3324/HAEMATOL.2013.096776

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_tzp4ne6ngfe6nmul3bsruybjqm

1 reference

https://api.fatcat.wiki/v0/release/tzp4ne6ngfe6nmul3bsruybjqm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33414445&oldid=1837554977"